Dominic Haertling
Internal Medicine · Perryville, MONPI 1558821413
Payments from drug & device makers
Across 131 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$554
- Lilly USA, LLC$370
- Novartis$235
- Novo Nordisk$225
- AstraZeneca$185
- Otsuka America Pharmaceutical, Inc.$145
- plus $623 from 16 others
What the payments were for
- Food & beverage$2,337100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $554 |
| Lilly USA, LLC | 20 | $370 |
| Novartis | 11 | $235 |
| Novo Nordisk | 12 | $225 |
| AstraZeneca | 8 | $185 |
| Otsuka America Pharmaceutical, Inc. | 7 | $145 |
| Exact Sciences | 4 | $81 |
| Bayer | 5 | $74 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $68 |
| Boehringer Ingelheim | 4 | $62 |
| Medtronic | 3 | $58 |
| GSK | 3 | $42 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Merck | 2 | $35 |
| Abiomed | 1 | $33 |
| Amgen | 2 | $32 |
| Pfizer | 1 | $21 |
| RGH Enterprises LLC | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Viatris Specialty LLC | 1 | $14 |
How this compares
$2,337 in reported general payments places this provider in the 80th percentile of 2,097 internal medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 39 | $45,429 |
| EliquisApixaban | 27 | $35,340 |
| XareltoRivaroxaban | 43 | $25,231 |
| MounjaroTirzepatide | 20 | $22,718 |
| TrulicityDulaglutide | 20 | $20,240 |
| FarxigaDapagliflozin Propanediol | 22 | $15,765 |
| Sumatriptan Succinate | 19 | $11,924 |
| GemtesaVibegron | 28 | $11,111 |
| MyrbetriqMirabegron | 16 | $10,746 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $10,439 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 21 | $5,773 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $3,746 |
| Propafenone Hcl | 13 | $1,742 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $1,508 |
| Atorvastatin Calcium | 199 | $1,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $225 | $45,42939 claims |
| Lilly USA, LLCMounjaro, Trulicity | $370 | $42,95840 claims |
| PfizerEliquis | $21 | $35,34027 claims |
| GSKTrelegy Ellipta, Arexvy | $42 | $16,21232 claims |
| AstraZenecaFarxiga | $185 | $15,76522 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $17 | $11,11128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Perryville
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.